```html

Zollinger’s Gastrinoma (Non‑Functional)

Overview

Zollinger–Ellison syndrome (ZES) is a rare disorder caused by gastrin‑secreting tumors (gastrinomas). When the tumor does not produce excess gastric acid or cause the classic peptic‑ulcer symptoms, it is referred to as a non‑functional gastrinoma. These tumors are usually part of ZES but may initially present without overt gastrointestinal complaints, making diagnosis challenging.

Most gastrinomas are malignant (≈ 60 % develop metastases) and arise in the “gastrinoma triangle” (the region bounded by the cystic duct, the second part of the duodenum, and the junction of the neck and body of the pancreas). Non‑functional tumors are slightly more common in men and tend to be diagnosed at a later stage because they lack the hallmark ulcer disease.

• Incidence: 0.5–2 cases per million people per year (Mayo Clinic).
• Prevalence: ≈ 3 – 5 cases per million in the United States (NIH).
• Median age at diagnosis: 45–55 years; 60–70 % are diagnosed after age 40.
• ≈ 25 % occur in patients with multiple endocrine neoplasia type 1 (MEN‑1).<sup>[1]</sup>

Symptoms

Because non‑functional gastrinomas do not cause excess gastric acid, symptoms are usually related to tumor size, local invasion, or metastasis rather than ulcer disease. Common manifestations include:

Mass‑related symptoms

• Abdominal pain or fullness – dull, persistent pain in the upper abdomen or a sensation of being “full” after small meals.
• Palpable abdominal mass – rare, but may be detected on physical exam for larger tumors.
• Weight loss – due to early satiety or catabolic effects of the tumor.

Hormone‑related but non‑acidic effects

• Fatigue/weakness – secondary to chronic disease and possible anemia.
• Hyperglycemia – gastrinomas may coexist with pancreatic beta‑cell neoplasia, especially in MEN‑1.

Symptoms of metastatic spread

• Liver involvement – right‑upper‑quadrant pain, jaundice, or enlarged liver on imaging.
• Bone pain – osteolytic lesions can cause chronic bone discomfort.
• Dyspnea – if lung metastases develop.

Rare endocrine manifestations

• Hypercalcemia – often linked to concurrent parathyroid hyperplasia in MEN‑1.
• Hypoglycemia – if a co‑existing insulinoma is present.

Causes and Risk Factors

Non‑functional gastrinomas are neuroendocrine tumors (NETs) that arise from enterochromaffin‑like (ECL) cells in the pancreas or duodenum.

Primary causes

• Genetic mutations – Sporadic cases often harbor somatic mutations in the MEN1 gene, DKFZ‑p27, and VHL. Germline MEN1 mutations cause hereditary MEN‑1 syndrome.
• Chromosomal alterations – Loss of heterozygosity on chromosome 11q13 (where MEN1 resides) is common.

Risk factors

• Family history of MEN‑1 or other endocrine tumors.
• Known germline MEN1 mutation.
• Previous radiation exposure to the abdomen (rare).
• Age > 40 years (peak incidence).
• Male sex – slight male predominance (≈ 55 % of cases).

Diagnosis

Diagnosis requires a combination of biochemical testing, imaging, and sometimes histologic confirmation. Because non‑functional tumors do not cause hyperacidity, the classic secretin stimulation test for ZES is less useful, but serum gastrin levels are still measured to assess tumor activity.

Biochemical tests

• Serum gastrin – Elevated (> 200 pg/mL) in > 80 % of gastrinomas, even if non‑functional. Fasting levels are preferred.
• Chromogranin A (CgA) – A general NET marker; elevated in 70‑80 % of cases.
• 24‑hour urinary 5‑HIAA – Usually normal unless the tumor produces serotonin.

Imaging studies

• Multiphasic contrast‑enhanced CT – First‑line; detects tumors > 1 cm with sensitivity ≈ 85 %.
• Magnetic resonance imaging (MRI) with diffusion‑weighted sequences – Improves detection of liver metastases; sensitivity ≈ 90 %.
• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – Gold standard for staging and locating occult lesions; sensitivity > 95 % for well‑differentiated NETs.<sup>[2]</sup>
• Endoscopic ultrasound (EUS) – Valuable for small pancreatic lesions (< 2 cm) and for tissue acquisition.

Histology

If imaging suggests resectable disease, fine‑needle aspiration (FNA) or core biopsy is performed. Pathology confirms neuroendocrine differentiation (positive for synaptophysin, chromogranin A) and grades the tumor based on Ki‑67 index:

• Grade 1: Ki‑67 < 3 %
• Grade 2: Ki‑67 3–20 %
• Grade 3: Ki‑67 > 20 % (more aggressive).

Treatment Options

Management is multidisciplinary, involving endocrine surgeons, medical oncologists, gastroenterologists, and radiologists.

Surgical resection

• Curative intent – En bloc resection of the primary tumor and regional lymph nodes (pancreaticoduodenectomy or distal pancreatectomy) is preferred for localized disease.
• Debulking surgery – For metastatic disease, removal of > 90 % of tumor burden can improve symptoms and hormone control.

Medical therapy

• Somatostatin analogues (SSAs) – Octreotide or lanreotide bind somatostatin receptors, inhibiting gastrin secretion and tumor growth. Effective in > 70 % of patients for disease stabilization.<sup>[3]</sup>
• Targeted therapies
  • Everolimus – mTOR inhibitor; modest progression‑free survival benefit in advanced NETs.
  • Sunitinib – Tyrosine‑kinase inhibitor; approved for pancreatic NETs.
• Chemotherapy – Typically reserved for high‑grade (Ki‑67 > 20 %) or rapidly progressive disease. Regimens include streptozocin‑based combos or temozolomide‑capecitabine.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers targeted radiation; shows 30‑40 % objective response in metastatic NETs with strong somatostatin receptor expression.<sup>[4]</sup>

Locoregional therapies for metastases

• Radiofrequency ablation (RFA) or microwave ablation for liver lesions.
• Transarterial chemoembolization (TACE) for unresectable hepatic disease.
• Liver transplantation – considered in highly selected patients with isolated liver metastases.

Lifestyle and supportive care

• Nutrition: Small, frequent meals; maintain adequate protein and calorie intake.
• Bone health: Calcium and vitamin D supplementation plus weight‑bearing exercise if bony metastases are present.
• Psychological support: Counseling or support groups for chronic disease management.

Living with Zollinger’s Gastrinoma (Non‑Functional)

Even after treatment, ongoing surveillance and self‑care are essential.

Follow‑up schedule

• Every 3–6 months: Serum gastrin, chromogranin A, and liver function tests.
• Imaging (CT or MRI) every 6–12 months, or sooner if symptoms change.
• Annual bone density scan if on long‑term SSA therapy (risk of osteoporosis).

Daily management tips

• Medication adherence – Never skip SSA injections; set reminders.
• Nutrition – Focus on balanced diet; avoid large, heavy meals that exacerbate abdominal fullness.
• Hydration – Aim for ≥ 2 L of water daily, unless fluid restriction is advised for heart or kidney disease.
• Physical activity – 150 minutes of moderate aerobic exercise per week improves fatigue and overall health.
• Watch for signs of progression – New abdominal pain, unexplained weight loss, jaundice, or bone pain should prompt a clinician visit.

Psychosocial well‑being

Living with a rare cancer can cause anxiety. Consider:

• Joining patient advocacy groups such as the Neuroendocrine Tumor Research Foundation (NETRF).
• Seeking counseling or cognitive‑behavioral therapy for stress management.
• Keeping a symptom diary to share with your care team.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling for individuals with a family history of MEN‑1; predictive testing can guide surveillance.
• Avoid unnecessary abdominal radiation – Discuss alternative imaging if you have a history of repeated CT scans.
• Healthy lifestyle – Smoking cessation and limiting alcohol may reduce overall cancer risk, though specific data for gastrinomas are lacking.

Complications

• Metastatic disease – Liver is the most common site; leads to hepatic dysfunction.
• Pancreatitis – Tumor invasion or surgery can provoke inflammation.
• Peptic ulcer disease – Although non‑functional, many patients eventually develop hypergastrinemia sufficient to cause ulcers.
• Carcinoid heart disease – Rare, but prolonged hormone secretion can affect heart valves.
• Osteoporosis – Chronic SSA therapy and possible hyperparathyroidism (MEN‑1) increase fracture risk.
• Psychological distress – Chronic illness may lead to depression or anxiety.

When to Seek Emergency Care

---

References:

1. American Association of Clinical Endocrinology. "Multiple Endocrine Neoplasia Type 1 (MEN1)." 2023.
2. Guerra, L., et al. “Ga‑68 DOTATATE PET/CT in Neuroendocrine Tumors: Diagnostic Accuracy and Clinical Impact.” J Nucl Med, 2022.
3. O’Reilly, D., et al. “Efficacy of Somatostatin Analogues in Gastrinomas.” Cleveland Clinic Journal of Medicine, 2021.
4. Kwekkeboom, D.J., et al. “Long‑Term Outcomes of 177Lu‑DOTATATE Therapy in Patients with Metastatic Neuroendocrine Tumors.” NEJM, 2020.

```